2022 Annual Conference on CNS Clinical Trials and Brain Metastases
2022 Annual Conference on CNS Clinical Trials & Brain Metastases,
Co-Sponsored by SNO and ASCO
Hilton Toronto, Toronto, Canada
Registration and Accommodation Links Coming Soon!
An interactive, interdisciplinary conference on primary and metastatic CNS malignancies.
The Second Annual Conference on CNS Clinical Trials and Brain Metastases, Co-Sponsored by SNO and ASCO — an interactive, interdisciplinary conference on primary and metastatic CNS malignancies — is being held August 12-13, 2022, in Toronto. The goal of this annual Conference is to provide a deeper dive into the area of neuro-oncology clinical trials, to understand how we can make more significant improvements in survival and quality of life of patients with primary and metastatic cancers of the central nervous system.
This collaborative conference will address the needs of patients with glioblastoma and intracranial malignancy in general, both primary and secondary, and stimulate clinical research in these areas of great unmet clinical need. Research advocating new approaches, out of the box ideas and reforms in the area of neuro-oncology clinical trials will be presented and discussed. The structure will provide a forum that cuts across a large breadth of disciplines and emphasizes aspects of clinical trial design, statistics and interpretation of trial outcomes to develop a better understanding of why numerous glioblastoma and other neuro-oncology clinical trials do not achieve their ultimate objective of prolonging survival of patients and other meaningful clinical measures. In addition, it will provide a forum that promotes collaboration and cross-fertilization of novel ideas between those invested in the care of patients with primary and secondary malignancies of the CNS.
Neuro-oncologists (both neurology and medical oncology-trained), Medical Oncologists, Neurosurgeons, Neuro-radiologists, Neuropathologists, Neuropsychologists, Radiation Oncologists, Basic and Translational Scientists, Basic and Clinical Science Trainees, Allied Health Professionals, Palliative Care Professionals, Industry Professionals, Regulatory and Government Officials, and Patient Advocates
Program Committee Co-Chairs
Priscilla Brastianos, Massachusetts General Hospital, Harvard Medical School
Mustafa Khasraw, Duke University
Program Committee Co-Chairs Elect
Adrienne Boire, Memorial Sloan Kettering Cancer Center
Sarah Goldberg, Yale School of Medicine
Program Committee Immediate Past Co-Chairs
Carey Anders, Duke Cancer Institute
Gelareh Zadeh, University Health Network, Toronto Western Hospital/University of Toronto
Evanthia Galanis, Mayo Clinic
Vinai Gondi, Northwestern Medicine Cancer Center Warrenville and Proton Center
Sara Hurvitz, University of California, Los Angeles; Jonnson Comprehensive Cancer Center
Rupesh Kotecha, Miami Cancer Institute
Emilie Le Rhun, University Hospital Zurich, Switzerland
Nancy Lin, Dana Farber Cancer Institute
Alireza Mansouri, Penn State Cancer Institute
Minesh Mehta, Miami Cancer Institute
Michael Platten, University Medical Center Mannheim
Mei-Yin C. Polley, University of Chicago
Solmaz Sahebjam, National Cancer Institute, National Institutes of Health
Hussein Tawbi, University of Texas MD Anderson Cancer Center